The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam’s Clinical Collaboration, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 29)
Stocks That Hit 52-Week Lows On Friday
Before 10 a.m. ET Friday, 117 stocks made new 52-week lows.
The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 22)
38 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Chembio Diagnostics, Inc. (NASDAQ: CEMI) shares jumped 218.7% to $6.57 after the company received a $28.3 million purchase order from Brazil's Bio-Manguinhos to purchase Chembio's DPP SARS-CoV-2 Antigen tests for delivery during 2021.
HC Wainwright & Co. Maintains Buy on Lumos Pharma, Lowers Price Target to $27
HC Wainwright & Co. analyst Edward White maintains Lumos Pharma (NASDAQ:LUMO) with a Buy and lowers the price target from $34 to $27.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's morning session saw 27 companies set new 52-week lows.
The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 20)
Lumos Pharma Delays Data Readout From Pediatric Growth Hormone Deficiency Trial To 2H Of 2023
Lumos Pharma Inc (NASDAQ: LUMO)